论文部分内容阅读
临床上长期使用降脂药物,因此了解其慢性毒性相当重要。60年代中期,国外陆续报导许多降脂药物能引起实验动物的肝肿大,同时伴有肝细胞超微结构的改变,主要是肝细胞过氧化体(Peroxisome)增生,并把能引起过氧化体增生的降脂药物称为降脂过氧化体增生剂(Hypolipidemic peroxisome pr-oliferator)。由于肝肿大和过氧化体的增生与给药时间有关,因而进行长期给药实验,结果表明,一些能引起肝肿大和过氧化体增生的降脂药物有致癌性。这一发现引起了人们的关注,本文概述有关进展。
Long-term clinical use of lipid-lowering drugs, so to understand its chronic toxicity is very important. In the mid-1960s, many overseas reports of lipid-lowering drugs can cause liver enlargement in experimental animals, accompanied by changes in the ultrastructure of liver cells, mainly liver cell peroxisome (Peroxisome) proliferation, and can cause peroxide Hyperlipidemic lipid-lowering drugs known as lipid-lowering peroxisome proliferator (Hypolipidemic peroxisome proliferator). Due to hepatomegaly and peroxisome hyperplasia and administration time, and therefore long-term administration experiments, the results show that some can cause hepatomegaly and peroxisomal proliferation of lipid-lowering drugs are carcinogenic. This discovery aroused people’s attention, this article outlines the progress.